POLICY NEWS · OCTOBER 2026
The Six Peptides in the HHS Policy: Routes and Pharmacy Requirements
The same headline covers six substances, but the policy treats their identities and routes differently. Here is the practical comparison, followed by the questions that matter when evaluating a pharmacy offering.
Status checked October 29, 2026: The official notice describes a draft policy, with publication scheduled for October 30. This is not FDA drug approval.
What this table describes
The table summarizes Appendix B of the HHS peptide enforcement-discretion policy. The associated Federal Register notice calls it a draft, filed October 28, 2026 and scheduled for publication October 30. This article reflects the public text checked October 29. The listed routes describe the policy’s scope, not treatment recommendations or approved indications.
| Substance and specified form | Routes described | Detail to check |
|---|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, topical | Oral formulation needs human bioavailability documentation. |
| TB-500 acetate | Subcutaneous or intramuscular | Specified seven-amino-acid fragment, not full-length thymosin beta-4. |
| Epitalon acetate | Subcutaneous or intramuscular | Dispensed in intermittent courses. |
| MOTS-c acetate | Subcutaneous or intramuscular | Exact identity and qualifying certificate of analysis. |
| Semax free base | Intranasal | The listed form and route do not describe injectable Semax. |
| KPV acetate | Topical or oral | Injectable KPV is not among these described routes; oral documentation applies. |
What should a pharmacy be able to explain?
The framework goes beyond a peptide name. It specifies original-manufacturer registration and manufacturing compliance, ingredient identity, certificates of analysis, testing and supplier validation where intermediaries are involved. It also includes reporting, labeling, delivery-device and patient-specific prescription conditions.
Our practical interpretation is to ask questions at three levels: who is providing clinical care, who prepares and dispenses the product, and what documentation connects the actual ingredient to that preparation. A clinic logo or a supplier’s generic purity badge answers none of those questions on its own.
Questions to ask before relying on an offering
- What is the exact preparation? Ask for the ingredient, salt or form, route and strength. Check those details against the policy rather than matching only the marketing name.
- Who is the dispensing pharmacy? Identify the actual pharmacy and ask whether it can dispense to your state. A telehealth website and a pharmacy perform different roles.
- How does the ingredient qualify? Ask how the pharmacy verifies the original manufacturer, the ingredient’s identity and its quality documentation. Registration of a facility is not FDA approval of the finished product.
- What supports an oral formulation? For oral BPC-157 or KPV, ask what human bioavailability documentation applies to the formulation being offered.
- What happens after a problem? Ask who handles clinical follow-up, suspected adverse events and quality complaints. Keep the product and batch details available for that discussion.
Which claims should readers question?
“All peptides are approved” is broader than a six-substance conditional framework. “Every route is covered” overlooks Appendix B. “The blend is covered because both ingredients appear” overlooks the single-API condition. “Available everywhere immediately” requires evidence beyond the public-inspection notice.
The BPC-157/TB-500 explainer works through the blend issue. The announcement timeline separates publication, comment and permanent rulemaking. These distinctions make it easier to evaluate the specific offer in front of you.
What remains a clinical decision?
A route appearing in a policy table does not establish the right dose, expected benefit or suitability for an individual. Ask what evidence supports the proposed use, which alternatives were considered and what follow-up is planned. Those questions remain relevant even when a pharmacy can document its supply chain.
FDA’s compounding guidance for patients explains the difference between a compounded medicine and an approved product. The October policy adds a specific regulatory development to that background; it does not replace the need to evaluate the treatment itself.